Assenagon Asset Management’s Spero Therapeutics SPRO Stock Holding History

Assenagon Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.5K	Sell	17,762 -874	-5%	-$1.19K	﹤0.01%	1095
2026 Q2	$41.2K	Hold	18,636	–	–	﹤0.01%	1158
2026 Q1	$43.6K	Hold	18,636	–	–	﹤0.01%	1095
2025 Q4	$43.4K	Sell	18,636 -18,357	-50%	-$42.6K	﹤0.01%	1140
2025 Q3	$69.5K	Buy	+36,993	New	+$81.3K	﹤0.01%	1156
2022 Q3	–	Sell	-131,020	Closed	-$97K	–	1531
2022 Q2	$97K	Buy	131,020 +107,897	+467%	+$314K	﹤0.01%	1410
2022 Q1	$201K	Buy	+23,123	New	+$237K	﹤0.01%	1358
2021 Q2	–	Sell	-181,578	Closed	-$2.67M	–	1397
2021 Q1	$2.67M	Buy	181,578 +57,793	+47%	+$1.02M	0.01%	649
2020 Q4	$2.4M	Buy	+123,785	New	+$1.93M	0.01%	486

Other funds holding SPRO

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Capital Asset Advisory Services Williamston, Michigan $2.94B AUM 11.83% 1-Year Est. Return

Three Seasons Wealth Salt Lake City, Utah $1.12B AUM 34.1% 1-Year Est. Return

Assenagon Asset Management's SPRO Position: Q3 2026 in Review

Assenagon Asset Management reduced its Spero Therapeutics (SPRO) stake by 4.7% in Q3 2026, selling an estimated $1.19K and leaving 17,762 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Assenagon Asset Management first reported a position in SPRO in Q4 2020 and has held it in 9 quarters since. The position peaked at $2.67M in Q1 2021. 22 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

Assenagon Asset Management held 17,762 shares of Spero Therapeutics worth $21.5K as of Q3 2026.
Assenagon Asset Management sold 874 Spero Therapeutics shares in Q3 2026, an estimated $1.19K.
Spero Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q3 2026, its #1095 holding.
Assenagon Asset Management first reported a position in Spero Therapeutics in Q4 2020 and has held it in 9 quarters since.
Assenagon Asset Management's Spero Therapeutics position peaked at $2.67M in Q1 2021.
22 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Assenagon Asset Management's 13F filing for Q3 2026, filed 15 Oct 2026.